Company Overview
Snapshot
Founded in January 2023 by Michael Vaknin, Lior Nissim, and Chezy Barenholtz, ViVac operates with 1–10 employees. The company is developing a nucleic acid-based vaccine platform and in November 2025 appointed Keren Leshem as Chief Executive Officer to strengthen its leadership.
Business overview
ViVac is advancing a viral vaccine platform designed to provide robust and long-lasting immunity against viral infections. The company's core technology focuses on nucleic acid-based vaccines that mimic actual viral infections, aiming to offer advantages over mRNA/DNA and traditional vaccines in terms of durability and cost-effective production. ViVac operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical and medical biotechnology industries with its drug delivery solutions.
Strategic signal
In November 2025, ViVac appointed Keren Leshem as Chief Executive Officer. This strategic leadership addition signals the company's focus on strengthening its executive team to advance its RNA–Lipid Nanoparticle (LNP) immunotherapy platform, indicating a push towards further development and potential commercialization in the competitive vaccine and immunotherapy market.
Log in to access full profile ›Company Intelligence Q&A
- When was ViVac founded?
- ViVac was founded in January 2023.
- Who are the founders of ViVac?
- ViVac was founded by Michael Vaknin, Lior Nissim, and Chezy Barenholtz.
- What is ViVac's primary focus?
- ViVac focuses on developing a revolutionary viral vaccine platform based on nucleic acids, designed to provide robust and long-lasting immunity by mimicking actual viral infections.
- What significant leadership change occurred at ViVac?
- In November 2025, ViVac appointed Keren Leshem as its Chief Executive Officer to strengthen leadership and advance its RNA-Lipid Nanoparticle immunotherapy platform.
- What is ViVac's core technology?
- ViVac's core technology is a nucleic acid-based viral vaccine platform that safely and precisely mimics actual viral infections to immunize against all viral proteins, aiming for robust and long-lasting immunity.